We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+7.75%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.7B
AUM Growth
+$80.1M
Cap. Flow
-$54.5M
Cap. Flow %
-1.47%
Top 10 Hldgs %
34.9%
Holding
147
New
53
Increased
24
Reduced
24
Closed
35

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$134M
2
LLY icon
Eli Lilly
LLY
+$114M
3
HOLX
Hologic
HOLX
+$80.8M
4
NEO icon
NeoGenomics
NEO
+$60.6M
5
BIIB icon
Biogen
BIIB
+$55.7M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$182M
2
ISRG icon
Intuitive Surgical
ISRG
+$103M
3
ABBV icon
AbbVie
ABBV
+$66.8M
4
MDT icon
Medtronic
MDT
+$61.4M
5
BHC icon
Bausch Health
BHC
+$60M

Sector Composition

Rank Sector Weight
1 Healthcare 95.4%
2 Technology 1.61%
3 Financials 0.67%
4 Consumer Discretionary 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COLL icon
126
Collegium Pharmaceutical
COLL
$1.15B
– –
-740,000
Closed -$17.5M
CRIS icon
127
Curis
CRIS
$9.14M
– –
-5,134
Closed -$23.2M
EYPT icon
128
EyePoint Inc
EYPT
$1.04B
– –
-232,504
Closed -$2.36M
IGMS
129
DELISTED
IGM Biosciences
IGMS
– –
-293,000
Closed -$22.5M
IMTX icon
130
Immatics
IMTX
$1.18B
– –
-884,600
Closed -$9.92M
INO icon
131
Inovio Pharmaceuticals
INO
$79.4M
– –
-333,699
Closed -$37.2M
ISRG icon
132
Intuitive Surgical
ISRG
$128B
– –
-418,200
Closed -$103M
KNSA icon
133
Kiniksa Pharmaceuticals
KNSA
$4.89B
– –
-1,330,700
Closed -$24.6M
KZR
134
DELISTED
Kezar Life Sciences
KZR
– –
-190,708
Closed -$11.4M
MRUS
135
DELISTED
Merus
MRUS
– –
-487,000
Closed -$10.2M
ORGO icon
136
Organogenesis Holdings
ORGO
$328M
– –
-1,463,403
Closed -$26.7M
TERN
137
DELISTED
Terns Pharmaceuticals
TERN
– –
-400,000
Closed -$8.8M
ZBH icon
138
Zimmer Biomet
ZBH
$17.8B
– –
-335,780
Closed -$52.2M
CMRX
139
DELISTED
Chimerix, Inc.
CMRX
– –
-2,230,000
Closed -$21.5M
EVLO
140
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
– –
-40,000
Closed -$8.56M
SGTX
141
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
– –
-65,459
Closed -$19M
ABMD
142
DELISTED
Abiomed Inc
ABMD
– –
-132,500
Closed -$42.2M
CCXI
143
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-940,800
Closed -$48.2M
ADMS
144
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-2,200,200
Closed -$10.6M
VSPRU
145
DELISTED
Vesper Healthcare Acquisition Corp. Unit
VSPRU
– –
-600,000
Closed -$6.93M
MSACU
146
DELISTED
Medicus Sciences Acquisition Corp. Unit
MSACU
– –
-520,000
Closed -$5.12M
BHVN
147
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-523,100
Closed -$35.8M
2 3 4 5
6

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q2 2021 Portfolio in Review

As of Q2 2021, Avidity Partners Management held 147 positions worth $3.7B, up 2.2% from $3.62B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Avidity Partners Management's Q2 2021 filing shows 53 new, 24 increased, 24 reduced and 35 closed positions. Its largest new stake was Eli Lilly: 565,500 shares worth $130M. The largest sale was AstraZeneca, an estimated $182M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Technology and Financials.

  • Avidity Partners Management's largest Q2 2021 buy was Eli Lilly: 565,500 shares worth $130M.
  • Avidity Partners Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $134M increase.
  • Avidity Partners Management's biggest Q2 2021 reduction was AbbVie, cutting an estimated $66.8M.
  • Avidity Partners Management fully exited AstraZeneca in Q2 2021, selling an estimated $182M.
  • Avidity Partners Management's ten largest holdings make up 35% of its $3.7B portfolio in Q2 2021.
  • Avidity Partners Management opened 53 new positions and closed 35 in Q2 2021.
  • Avidity Partners Management's portfolio value rose 2.2% quarter-over-quarter to $3.7B.

Based on Avidity Partners Management's 13F filing for Q2 2021, filed 16 Aug 2021.